Abstract | BACKGROUND: PATIENTS AND METHODS: RESULTS: Fifteen patients with histologically proven cT4b (three patients) and cT4d (twelve patients) M0 breast cancer were enrolled. Median age was 48 years (range 25-66). Eight clinical responses including one pathological complete remission (pCR), three stable disease (including minor responses) and four progression of disease, one during AC and three during taxotere, were observed. Four patients had grade 3-4 non hematological toxicities and all except one discontinued treatment. CONCLUSION: Due to the high rate of progressive disease, this schedule should not represent a standard option in cT4 breast cancer.
|
Authors | R Torrisi, L Orlando, R Ghisini, P Veronesi, M Intra, A Rocca, A Balduzzi, A Cardillo, A Goldhirsch, M Colleoni |
Journal | Anticancer research
(Anticancer Res)
2006 Sep-Oct
Vol. 26
Issue 5B
Pg. 3861-4
ISSN: 0250-7005 [Print] Greece |
PMID | 17094414
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Taxoids
- Docetaxel
- Doxorubicin
- Cyclophosphamide
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, therapeutic use)
- Breast Neoplasms
(drug therapy)
- Cyclophosphamide
(administration & dosage)
- Docetaxel
- Dose-Response Relationship, Drug
- Doxorubicin
(administration & dosage)
- Female
- Humans
- Middle Aged
- Taxoids
(administration & dosage)
- Treatment Outcome
|